checkAd
    Rani Therapeutics Holdings Registered (A) Aktie
    5,2500
     
    USD
    +2,14 %
    +0,1100 USD
    Letzter Kurs 18:52:26 Nasdaq
    5,2300
     
    USD
    800 STK
    Geldkurs 18:56:20
    5,2900
     
    USD
    300 STK
    Briefkurs 18:56:20
    ISIN: US7530181004 · WKN: A3CWFZ · SYM: RANI · USA

    Neueste Nachrichten

    Rani Therapeutics to Participate in May Investor Conferences
    14.05.24 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill Capsule at Digestive Disease Week 2024
    09.05.24 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
    06.05.24 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
    20.03.24 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
    15.03.24 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
    05.02.24 · globenewswire · Rani Therapeutics Holdings Registered (A)
    The RaniPill Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study
    25.10.23 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
    19.10.23 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
    12.10.23 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill Containing Ustekinumab Biosimilar, CT-P43)
    18.09.23 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
    07.09.23 · globenewswire · Rani Therapeutics Holdings Registered (A)
    Rani Therapeutics to Participate in September Investor Conferences
    06.09.23 · globenewswire · Rani Therapeutics Holdings Registered (A)